Highest-materiality recent filing
Seer Q2 2026 revenue down 23% to $3.1M; net loss $16.9M; reaffirms FY26 guidance
Revenue $3.1M vs $4.1M in Q2 2025, a 23% decline on macro headwinds and longer sales cycles.
Seer CEO Omid Farokhzad proposes to take company private at $2.45/share plus two CVRs
CEO Omid Farokhzad proposes to acquire all outstanding shares for $2.45/share cash plus two CVRs (Revenue-Linked up to $0.25, Sale-Linked up to $2.91).
CEO Omid Farokhzad proposes $2.45/share cash plus two CVRs (revenue-linked up to $0.33, sale-linked up to $4.91), total potential $7.69/share.
Seer Board Special Committee Rejects CEO Farokhzad's $2.45/Share Buyout Bid
Special Committee unanimously rejects unsolicited proposal from CEO Omid Farokhzad to acquire all shares for $2.45/share cash plus two CVRs.
Seer CEO Omid Farokhzad proposes to take company private at $2.45/share cash plus two CVRs
CEO Omid Farokhzad offers $2.45/share cash (41% premium to 30-day VWAP) plus Revenue-Linked CVR up to $0.25/share and Sale-Linked CVR up to $2.91/share.
Seer Board Unanimously Rejects $2.40/Share Cash Plus CVR Bid from Radoff-JEC Group
Board unanimously rejected May 14 revised proposal at $2.40/share cash plus contingent value right.
Seer Q1 2026 revenue $2.8M (-34% YoY); reaffirms FY2026 guidance of $16M-$18M
Revenue $2.8M, down 34% from $4.2M YoY, driven by depressed academic funding and competitive activity.
Seer appoints Anthony Bazarko as Chief Commercial Officer
Anthony Bazarko named CCO effective May 4, 2026; previously President & CEO of Biologos and CCO at Specific Diagnostics.
Seer Board unanimously rejects revised $2.35/share takeover bid from Radoff-JEC Group
Revised proposal from Radoff/JEC offers $2.35/share plus contingent value right; board says significantly undervalues Seer.
Seer receives unsolicited $2.25/share buyout proposal from Radoff-JEC Group
Radoff-JEC Group proposed to acquire all Seer shares for $2.25 per share cash plus a contingent value right.
PTAB upholds 23 claims of Seer's particle proteomics patent in Bruker challenge
PTAB Final Written Decision on March 23, 2026, upholds five challenged and 18 unchallenged claims of U.S. Patent No. 11,435,360.
Seer amends Tax Benefit Preservation Plan, pays $250K mootness fee to settle suit
Amended definition of 'Beneficial Ownership' in Tax Benefit Preservation Plan to address stockholder lawsuit.
Seer Q4 revenue $4.2M (+5% YoY); FY 2026 guidance $16-18M implies ~3% midpoint growth
Q4 2025 revenue $4.2M, up 5% YoY from $4.0M; product revenue $2.8M, service $1.2M.
Seer adopts tax-benefit preservation plan (poison pill) to protect NOLs; triggers at 4.9% ownership
Board declared dividend of one Right per common share, record date March 9, 2026.
Seer converts all Class B stock to Class A, ending dual-class voting
All outstanding Class B shares automatically converted into Class A on a 1:1 basis at close of business Dec. 9, 2025.
Seer Q3 2025 revenue $4.1M, net loss $18.2M; reaffirms FY25 revenue guidance $17-18M
Revenue $4.1M (+2% YoY); product revenue $2.8M, service revenue $1.2M, including $300K related party.
Seer appoints Isaac Ro to Board of Directors; grants initial equity award
Isaac Ro appointed to Seer board effective Sept 2, 2025, also named to Audit Committee as financial expert.
Seer Q2 revenue $4.1M (+32% YoY); launches Proteograph ONE & SP200
Revenue of $4.1M for Q2 2025, up 32% from $3.1M a year ago, driven by product and service revenue.
Seer non-compliant with Nasdaq Audit Committee rule after annual meeting; cure period sought
On July 7, 2025, notified Nasdaq that post-annual meeting it will not comply with Rule 5605(c)(2)(A) requiring at least three Audit Committee members, one with financial sophistication.
Revenue $4.2M, up 37% from $3.1M YoY, driven by higher product sales and service revenue.
Seer Q4 revenue down 10% YoY to $4.0M; full-year net loss $86.6M; guides 2025 rev $17-18M
Q4 2024 revenue $4.0M (-10% YoY); full-year 2024 revenue $14.2M (-15% YoY).
Seer Q3 2024 revenue $4.0M, net loss $21.3M; FY guidance reaffirmed $13-15M
Q3 revenue $4.0M vs $4.2M YoY (down 3%); product revenue $3.1M, service $847K, grant $90K.
Seer reprices ~7.9M underwater options to $2.00; CEO/CFO affected
Board approved repricing of ~7.9M underwater options (original strike $2.08-$60.15) to $2.00 per share.
Seer appoints Nicolas Roelofs to board as Lead Independent Director effective Aug 13, 2024
Roelofs replaces David Hallal as Lead Independent Director and joins CG&N and Science & Technology committees.
Seer Q2 revenue $3.1M (-23% YoY); FY 2024 guidance cut to $13-15M
Revenue $3.1M, down 23% YoY from $4.0M; product revenue $2.2M, service $845K.
Seer CLO resigns; David Hallal appointed to Audit Committee, resolving Nasdaq compliance
Elona Kogan resigns as Chief Legal Officer and Corporate Secretary effective July 26, 2024; departure not related to any disagreement.
Seer director resigns; company out of compliance with Nasdaq Audit Committee rule
Dr. Rachel Haurwitz resigned from Seer's Board and all committees effective July 8, 2024.
Seer stockholders elect four directors and ratify Deloitte as auditor at 2024 annual meeting
Quorum achieved with 82.8M votes representing 81.7% of eligible votes.
Seer Q1 revenue down 24% YoY to $3.1M; net loss narrows to $20.7M; authorizes $25M buyback
Revenue $3.1M (-24% YoY); product revenue $2.5M (incl. $828K related party), service $534K.
Seer reports Q4 revenue down 4% YoY to $4.4M; FY revenue up 8% to $16.7M
Q4 2023 net loss $17.8M narrowed from $22.5M; FY net loss $86.3M vs $93.0M prior year.
Seer director Catherine Friedman resigns; board reduced to 7; audit chair changed
Catherine Friedman resigned from the Board effective December 21, 2023, reducing board size from 8 to 7.
Seer promotes David Horn to President, appoints Elona Kogan as Chief Legal Officer
David Horn (CFO & Treasurer) adds President role; Omid Farokhzad resigns as President but remains CEO and Chair.
Seer Q3 revenue $4.2M (+5% YoY), net loss $21.1M; guides to lower half of FY range
Revenue $4.2M (+5% YoY); product revenue $3.3M incl $1.4M related party; service $536K; grant $348K.
Seer Q2 revenue $4M (+11% YoY); slashes FY2023 guidance to $16-18M from $23-25M
Net loss widened to $23.4M from $22.8M YoY; operating expenses rose 21% to $30.2M.
Seer board member Mostafa Ronaghi resigns effective immediately; board size reduced to 8
Mostafa Ronaghi, Ph.D. resigned from Seer's Board of Directors and all committees on July 18, 2023.
Seer shareholders approve board declassification; two directors receive over 24% withhold votes
Declassification proposal approved: 77.5M for, 5.9K against, 4.0M broker non-votes; certificate amended June 14.
Seer Q1 revenue $4.1M, up 22% YoY; net loss $24M; FY23 guidance reaffirmed $23-25M
Revenue $4.1M, up 22% YoY driven by consumable kit sales including $1.3M related party.
Seer Q4 revenue $4.6M (+50% YoY); FY22 revenue $15.5M (+134%); guides FY23 $23-25M
Q4 2022 revenue $4.6M, up 50% from $3.1M in Q4 2021; product revenue $3.2M including $1.7M related party.
Seer Q3 revenue $4.0M, net loss $24.0M; FY2022 guidance reaffirmed
Revenue of $4.0M, up 82% YoY from $2.2M, driven by Proteograph product suite sales.
Seer President Omead Ostadan resigns; CEO Omid Farokhzad becomes President
Ostadan resigns as President and from the Board effective Sep 30, 2022 for personal reasons.
Seer Q2 2022 revenue $3.6M, net loss $22.8M; guidance reaffirmed
Revenue $3.6M vs $1.3M YoY; product revenue $3.5M including $1.1M from related party.
Seer stockholders elect three directors, ratify Deloitte, approve say-on-pay every 3 years
Elected Robert S. Langer, Rachel Haurwitz, and Dipchand (Deep) Nishar as Class II directors; each received over 82% of votes cast.
Seer reports Q1 revenue $3.3M, net loss $23.6M; reaffirms FY2022 guidance $14-16M
Revenue $3.3M (vs $62K Q1 2021); product revenue $3.2M incl. $1.1M related-party.
Seer appoints Scott Thomas as Chief Commercial Officer effective March 21, 2022
Scott Thomas appointed CCO, effective March 21, 2022; previously SVP at Singular Genomics and various roles at Illumina.
Seer Q4 2021 rev $3.1M, FY rev $6.6M; guides FY2022 rev $14-16M
Q4 revenue $3.1M (up from $336K YoY); net loss $19.7M vs $12.9M.
Seer President & COO Omead Ostadan returns from leave, shifts to part-time for ~10 months
Ostadan returns Feb 28, 2022 as President on part-time (33% status) for ~10 months.
Seer appoints Meeta Gulyani to Audit Committee; Deep Nishar resigns from committee
Meeta Gulyani appointed to Audit Committee effective January 18, 2022.
Appointed Meeta Gulyani as Class III director with term expiring at 2023 annual meeting.
Seer Q3 2021 revenue $2.2M, net loss $18.4M; on track for broad release in early 2022
Revenue $2.2M vs $72K in Q3 2020; product-related revenue $1.6M including $787K from related party.
Seer appoints Rachel Haurwitz, Ph.D. to its board; David Singer resigns
Dr. Haurwitz, CEO of Caribou Biosciences, appointed to Seer board effective Nov. 8, 2021 as Class II director.
On August 13, 2024, the board of directors (the “Board”) of Seer, Inc. (the “Company”) appointed Nicolas Henry Roelofs, Ph.D. to the Board with a term expiring at the Company’s 2025 annual meeting of the stockholders.
The Company also announced that Dr. Roelofs would replace David Hallal as the Company’s Lead Independent Director and would serve on the Company’s Corporate Governance and Nominating Committee and Science and Technology Committee.
On July 16, 2024, Elona Kogan resigned as the Chief Legal Officer and Corporate Secretary of Seer, Inc. (the “Company”), to pursue other career opportunities.
On July 8, 2024, Rachel Haurwitz, Ph.D. informed Seer, Inc. (the “Company”) of her resignation as a member of the Company’s Board of Directors (the “Board”) and all committees thereof, effective immediately
On December 21, 2023, Catherine Friedman informed Seer, Inc. (the “Company”) of her resignation as a member of the Company’s Board of Directors (the “Board”) and all committees thereof, effective immediately.
Omid Farokhzad, M.D. resigned from the position of President of the Company; he will retain his positions as Chief Executive Officer and Chair of the Board of Directors
On November 17, 2023, in connection with the promotion of David Horn to the office of President of Seer, Inc. (the “Company”), in addition to his current position as Chief Financial Officer
Also on November 17, 2023, the Board appointed Elona Kogan to the office of Chief Legal Officer of the Company.
On July 18, 2023, Mostafa Ronaghi, Ph.D. informed Seer, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and all committees thereof, effective immediately.
On August 25, 2022, Omead Ostadan resigned from his position as President of Seer, Inc. (the “Company”) and from its Board of Directors (the “Board”) for personal reasons, each effective as of September 30, 2022.
In addition, on August 26, 2022, the Board appointed Omid Farokhzad, M.D. to the office of President of the Company, in addition to his current positions as Chief Executive Officer and Chair of the Board, effective as of Mr. Ostadan’s resignation.
On August 25, 2022, Omead Ostadan resigned from his position as President of Seer, Inc. (the “Company”) and from its Board of Directors (the “Board”) for personal reasons, each effective as of September 30, 2022.
Max materiality 0.90 · Median 0.60 · Most common event earnings